Business Model
YM BioSciences is a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development.
 
Nimotuzumab
Anti-cancer antibody that targets the epidermal growth factor receptor, with an improved side-effect profile compared to marketed EGFR-targeting products
AeroLEF®
Proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl
CYT387
Novel JAK1/JAK2 inhibitor for multiple indications including MPNs
CYT997
Novel anti-cancer Vascular Disrupting Agent (VDA)
 
   
consortium
 
science
dosing
 
science
 
clinical trials
 
safety profile
clinical trials
news
events
webcasts

 

February 8, 2010
3:30 PM (EST)
12th Annual BioCEO & Investor Conference
Duke of Windsor Room
Waldorf=Astoria Hotel
New York, NY
Presenter: David Allan
listen to webcast 

November 19, 2009
4:00 PM (EST)
YM BioSciences Annual General Meeting
of Shareholders
TSX Broadcast Centre Gallery
The Exchange Tower
130 King Street W., Toronto, Ontario
listen to archived webcast | view AGM presentation

presentations
reports
posters & publications

Corporate Presentation
Calendar First Quarter 2010

Nimotuzumab Proposed Mechanism of Action

The AeroLEF Concept

2009 Annual Report

Letter from the CEO: Update for Investors in YM BioSciences Inc.

U.S. Senate Report on Changing Cuba Policy


 

Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non-toxic in a preclinical model of advanced triple negative breast cancer. Lead author: Anthony J. Mutsaers, Sunnybrook Health Sciences Centre (2009 AACR Molecular Targets and Cancer Therapeutics)

ASCO 2009 poster presentation reporting results from a randomized trial of nimotuzumab (aka BIOMab/TheraCIM/h-R3) in patients with head & neck cancer. Conducted by Biocon Limited (Bangalore, India), a licensee of CIMAB SA, YM's licensor.


Binding properties of the anti-EGFR monoclonal antibody, nimotuzumab, limit interaction with the EGFR in renal and epidermal cells (2009 AACR Annual Meeting)